Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
April 10th, 2020
Zebrafish xenograft models allow for high-throughput drug screening and fluorescent imaging of human cancer cells in an in vivo microenvironment. We developed a workflow for large scale, automated drug screening on patient-derived leukemia samples in zebrafish using an automated fluorescence microscope equipped imaging unit.
Overview
This study presents a zebrafish xenograft drug screening workflow that enables automated imaging and quantification of human cancer cells. The method allows for rapid testing of patient-derived leukemia samples against known drugs and the identification of new anticancer compounds.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Drug Screening
Background
- Zebrafish models provide an in vivo environment for cancer research.
- Automated imaging enhances the efficiency of drug response evaluation.
- Patient-derived samples offer a more relevant model for testing.
- Cost-effectiveness compared to traditional mouse models.
Purpose of Study
- To develop a workflow for high-throughput drug screening.
- To automate the imaging process for better quantification of drug responses.
- To facilitate the identification of new anticancer compounds.
Methods Used
- Injection of cancer cells into zebrafish.
- Automated fluorescence microscopy for imaging.
- Quantification of drug responses in vivo.
- Testing against large libraries of compounds.
Main Results
- Successful imaging and quantification of human cancer cells.
- Rapid assessment of drug responses in patient-derived samples.
- Identification of potential new anticancer compounds.
- Demonstrated cost-effectiveness of zebrafish models.
Conclusions
- The zebrafish xenograft model is a valuable tool for drug screening.
- Automated workflows enhance research efficiency.
- This approach may lead to better therapeutic options for leukemia.
Frequently Asked Questions
Executive Industry Relevance
Zebrafish patient-derived xenograft (PDX) drug screening enables rapid, high-throughput in vivo evaluation of cancer therapies, addressing the need for scalable, cost-effective models in early oncology discovery. This workflow supports predictive confidence in drug response by combining large replicate numbers with automated quantification, bridging the gap between in vitro screens and traditional mouse PDX models. The approach enhances portfolio triage and accelerates actionable insights for translational oncology programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of patient tumor samples in a living system for target validation.
- Supports biological de-risking by providing in vivo context for drug response.
- Facilitates rapid hypothesis testing across diverse compound libraries.
- Improves predictive confidence for advancing candidate therapies.
Screening & Assay Development
- Delivers standardized, quantitative readouts of tumor area and drug response using automated imaging.
- Enables high-throughput screening with large replicate numbers previously limited to in vitro systems.
- Supports reproducibility and scalability for compound evaluation workflows.
- Prepares validated in vivo models for downstream translational studies.
Translational & Preclinical Research
- Aligns drug response data with patient-specific tumor biology for translational relevance.
- Provides continuity from discovery through preclinical validation using clinically derived samples.
- Enables risk-adjusted advancement decisions based on in vivo efficacy signals.
- Supports identification of actionable mutations and targeted therapy responses.
Pipeline & Workflow Integration
This zebrafish PDX screening method integrates from early discovery through lead identification and preclinical validation, offering a scalable alternative to mouse models for in vivo drug response assessment.
- Discovery Biology: Supports hypothesis testing and pathway clarification using patient-derived tumor cells in vivo.
- Screening: Provides assay readiness and reproducible, quantitative outputs for large-scale compound evaluation.
- Analytics: Delivers automated measurements of tumor area and drug response for robust statistical comparison.
- Translational Research: Bridges discovery and preclinical stages with patient-relevant efficacy data.
- Enterprise Reuse: Establishes a reusable, standardized platform for oncology drug screening across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in early oncology discovery.
- Operational Value: Enhances standardization, reproducibility, and scalability of in vivo drug screening.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling rapid, cost-effective in vivo assessment.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets.
Implementation Considerations
- Requires expertise in zebrafish handling, microinjection, and fluorescence imaging.
- Needs access to automated imaging platforms and analytical software for quantification.
- Demands cross-team standardization of injection, imaging, and analysis protocols.
- Adaptation may be needed for different tumor types or targeted therapies.
- Current limitations include automation and quantification scalability for larger screening campaigns.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:54
Fluorescently Labeling Cells with DiI(1,1 -Dioctadecyl-3,3,3 ,3 -Tetramethylindocarbocyanine Perchlorate)
2:10
Microinjecting Zebrafish Larvae
4:37
Setting up Drug Screen with Xenografted Zebrafish
6:22
Imaging Xenografted Zebrafish and Quantifying Fluorescence
8:36
Results: Xenografted Tumor Area
9:22
Conclusion
